{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T23:17:57Z","timestamp":1777936677850,"version":"3.51.4"},"reference-count":30,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Clin Med Insights Oncol"],"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Malignant peritoneal mesothelioma (MPeM) is a rare and progressive cancer originating from the mesothelial cells of the peritoneum. In patients with early-stage disease who are suitable for surgery, the treatment of choice is CRS\u2009+\u2009HIPEC, whereas in advanced-stage patients, systemic treatments are applied. Pemetrexed plus platinum regimens are at the forefront of first-line systemic treatments. Gemcitabine plus platinum regimens are rarely used as first-line treatment for MPeM. The aim of our study is to compare the efficacy of first-line pemetrexed plus platinum with gemcitabine plus platinum regimens in patients with MPeM.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>In this study, a retrospective analysis was conducted on 48 patients with MPeM who were followed up in our clinic between 2001 and 2025. In our study, 28 patients received pemetrexed plus platinum as a first-line regimen, while 20 patients received gemcitabine plus platinum. The median overall survival (OS), median progression-free survival (PFS), and response rates for both regimens were analyzed. In addition, prognostic factors influencing overall survival were investigated in the entire patient population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>The median PFS and OS were 11.1\u2009months and 17.0\u2009months for pemetrexed and 8.01\u2009months and 14.4\u2009months for gemcitabine. Although pemetrexed showed numerically higher PFS and OS, the difference was not statistically significant. The objective response rate (ORR) and disease control rate (DCR) were 32.1% and 57.1% for pemetrexed, compared with 25% and 40% for gemcitabine, showing pemetrexed\u2019s superiority in response rates. In the entire patient population, CRS\u2009+\u2009HIPEC was the main prognostic factor for survival.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>We have demonstrated that the pemetrexed\u2009+\u2009platinum regimen has better response rates compared with the gemcitabine\u2009+\u2009platinum regimen in MPeM patients. However, gemcitabine-based regimens can be used as an alternative to pemetrexed in patients with MPeM.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/11795549251385075","type":"journal-article","created":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T04:18:16Z","timestamp":1760761096000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparison of the Efficacy of First-Line Pemetrexed-Platinum and Gemcitabine-Platinum Regimens in Malignant Peritoneal Mesothelioma"],"prefix":"10.1177","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5976-2494","authenticated-orcid":false,"given":"Do\u011fan","family":"Bayram","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Ankara City Hospital, Ankara, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9586-2858","authenticated-orcid":false,"given":"Safa Can","family":"Efil","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Ankara City Hospital, Ankara, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Serap","family":"T\u00fcrk","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Ankara City Hospital, Ankara, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O\u011fuz","family":"Kara","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Ankara City Hospital, Ankara, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4650-248X","authenticated-orcid":false,"given":"Serhat","family":"Sekmek","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Ankara City Hospital, Ankara, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u015eebnem","family":"Y\u00fccel","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Ankara City Hospital, Ankara, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Selin","family":"Akt\u00fcrk Esen","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Ankara City Hospital, Ankara, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G\u00f6khan","family":"U\u00e7ar","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Ankara City Hospital, Ankara, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oznur","family":"Bal","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Ankara City Hospital, Ankara, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Efnan","family":"Algin","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Ankara City Hospital, Ankara, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Do\u011fan","family":"Uncu","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Ankara City Hospital, Ankara, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2025,10,17]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.soc.2018.02.010"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.09.012"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1097\/PAT.0b013e3283631cce"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr.2018.10.04"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11864-008-0067-z"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdl345"},{"key":"e_1_3_3_8_2","first-page":"79","article-title":"Diagnosis and management of patients with malignant peritoneal mesothelioma","volume":"7","author":"Alexander HR","year":"2016","unstructured":"Alexander HRJr, Burke AP. Diagnosis and management of patients with malignant peritoneal mesothelioma. J Gastrointest Oncol. 2016;7:79-86.","journal-title":"J Gastrointest Oncol"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1080\/02656736.2017.1320591"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.23.9640"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4613-1247-5_23"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25640"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.04.150"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.3816\/CLC.2005.n.020"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-021-08025-x"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1993.140"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61602-X"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.11.136"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6600505"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.1.25"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0031-1272874"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-014-3978-x"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2008.08.013"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1080\/14737140.2017.1340157"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyz104"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6600118"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11405"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(21)00043-6"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.2526"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(24)00119-X"}],"container-title":["Clinical Medicine Insights: Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/11795549251385075","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/11795549251385075","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/11795549251385075","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T03:40:28Z","timestamp":1777693228000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/11795549251385075"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":30,"alternative-id":["10.1177\/11795549251385075"],"URL":"https:\/\/doi.org\/10.1177\/11795549251385075","relation":{},"ISSN":["1179-5549","1179-5549"],"issn-type":[{"value":"1179-5549","type":"print"},{"value":"1179-5549","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1]]},"article-number":"11795549251385075"}}